CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Toronto, Ontario, Canada and 173 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Toronto, Canada and 47 other locations
single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...
Phase 1
Toronto, Ontario, Canada and 13 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Brampton, Ontario, Canada and 108 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Toronto, Ontario, Canada and 23 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Toronto, Ontario, Canada and 110 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Toronto, Ontario, Canada and 85 other locations
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia...
Phase 1, Phase 2
Toronto, Ontario, Canada and 42 other locations
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
Toronto, Ontario, Canada and 125 other locations
The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...
Phase 3
Toronto, Ontario, Canada and 240 other locations
Clinical trials
Research sites
Resources
Legal